Literature DB >> 15522553

Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.

F Denis1, A V Desbiez-Bourcier, C Chapiron, F Arbion, G Body, L Brunereau.   

Abstract

AIMS: We prospectively compared the ability of magnetic resonance imaging (MRI) to measure residual breast cancer in patients treated with different neoadjuvant chemotherapy regimen.
METHODS: Forty patients with locally advanced breast carcinoma underwent neoadjuvant chemotherapy. Twelve patients received 5-fluoro-uracyl-epirubicin-cyclophosphamide (FEC-group, six cycles), 28 (DXL-group) received docetaxel-based chemotherapy (six cycles DXL-epirubicin: 13 patients, eight cycles DXL alone: 15 patients). All patients had baseline and preoperative MRI. The spread of pathologic residual disease (PRd) was compared to preoperative MRI measures according to chemotherapy regimen.
RESULTS: MRI over/underestimation of the spread of residual tumour was never superior to 15mm in FEC group, whereas it appeared in 11/28 (39%, 30-48%-95% CI) patients in DXL group (p=0.017). Tumour shrinkage led to single nodular residual lesions in FEC group, whereas vast numerous microscopic nests were observed in docetaxel group in pathology.
CONCLUSION: Among tumours treated with a taxane-containing regimen, residual disease was frequently underestimated by MRI because of PRd features.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522553     DOI: 10.1016/j.ejso.2004.07.024

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  24 in total

1.  Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.

Authors:  Anees B Chagpar; Lavinia P Middleton; Aysegul A Sahin; Peter Dempsey; Aman U Buzdar; Attiqa N Mirza; Fredrick C Ames; Gildy V Babiera; Barry W Feig; Kelly K Hunt; Henry M Kuerer; Funda Meric-Bernstam; Merrick I Ross; S Eva Singletary
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

2.  Accuracy of Contrast-Enhanced Ultrasound Compared With Magnetic Resonance Imaging in Assessing the Tumor Response After Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Sandy C Lee; Edward Grant; Pulin Sheth; Agustin A Garcia; Bhushan Desai; Lingyun Ji; Susan Groshen; Darryl Hwang; Mary Yamashita; Linda Hovanessian-Larsen
Journal:  J Ultrasound Med       Date:  2017-02-02       Impact factor: 2.153

3.  Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer.

Authors:  Jason D Keune; Donna B Jeffe; Mario Schootman; Abigail Hoffman; William E Gillanders; Rebecca L Aft
Journal:  Am J Surg       Date:  2010-04       Impact factor: 2.565

4.  Prognostic imaging in neoadjuvant chemotherapy of locally-advanced breast cancer should be cost-effective.

Authors:  Marc Schegerin; Anna N A Tosteson; Peter A Kaufman; Keith D Paulsen; Brian W Pogue
Journal:  Breast Cancer Res Treat       Date:  2008-04-25       Impact factor: 4.872

5.  A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyond.

Authors:  C E Simmons; S Hogeveen; R Leonard; Y Rajmohan; D Han; A Wong; J Lee; M Brackstone; J F Boileau; R Dinniwell; S Gandhi
Journal:  Curr Oncol       Date:  2015-03       Impact factor: 3.677

6.  Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.

Authors:  Aida Kuzucan; Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Peter T Fwu; Hon J Yu; David J B Hsiang; Karen T Lane; John A Butler; Stephen A Feig; Min-Ying Su
Journal:  Clin Breast Cancer       Date:  2012-04       Impact factor: 3.225

7.  MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer.

Authors:  Stephen F Sener; Rachel E Sargent; Connie Lee; Tejas Manchandia; Vivian Le-Tran; Yuliya Olimpiadi; Nicole Zaremba; Andrew Alabd; Maria Nelson; Julie E Lang
Journal:  J Surg Oncol       Date:  2019-08-09       Impact factor: 3.454

8.  Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.

Authors:  Nola M Hylton; Constantine A Gatsonis; Mark A Rosen; Constance D Lehman; David C Newitt; Savannah C Partridge; Wanda K Bernreuter; Etta D Pisano; Elizabeth A Morris; Paul T Weatherall; Sandra M Polin; Gillian M Newstead; Helga S Marques; Laura J Esserman; Mitchell D Schnall
Journal:  Radiology       Date:  2015-12-01       Impact factor: 11.105

9.  Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology.

Authors:  Jeon-Hor Chen; Shadfar Bahri; Rita S Mehta; Philip M Carpenter; Christine E McLaren; Wen-Pin Chen; Peter T Fwu; David J B Hsiang; Karen T Lane; John A Butler; Min-Ying Su
Journal:  J Surg Oncol       Date:  2013-10-28       Impact factor: 3.454

10.  Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.

Authors:  J Dose-Schwarz; R Tiling; S Avril-Sassen; S Mahner; A Lebeau; C Weber; M Schwaiger; F Jänicke; M Untch; N Avril
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.